We have previously described a subpopulation of patients with septic shock who had a reversible depression of radionuclide-determined left ventricular ejection fraction (EF). To investigate the mechanism of this myocardial depression, an in vitro model of mammalian myocardial cell performance was established employing primary spontaneously beating rat myocardial cells. The contraction of a single cardiac cell was quantitated by recording the changes in area occupied by the cell during contraction and relaxation. In 20 septic shock patients during the acute phase, the mean left ventricular EF was decreased (mean = 0.33, normal mean = 0.50), and serum obtained during this acute phase induced a mean (+/-standard error of the mean) 33 +/-4% decrease in extent and 25 +/-4% decrease in velocity of myocardial cell shortening during contraction (P less than 0.001). In contrast, serum obtained from 11 of these same patients before shock (n = 2) or after recovery (n = 9) of the left ventricular EF (mean = 0.50) showed a return toward normal in extent and velocity of shortening (P less than 0.001). Sera from 17 critically ill nonseptic patients, from 10 patients with structural heart disease as a cause for a depressed EF, and from 12 healthy laboratory personnel, induced no significant changes in in vitro myocardial cell performance. 
Introduction
Serious cardiovascular compromise resulting from bloodstream invasion by microorganisms represents one ofthe most common life-threatening clinical syndromes in medicine. Shock secondary to sepsis has been the subject ofan enormous investigative effort during the past 40 years; however, it remains a common cause of patient demise (1, 2) . The pathogenesis of septic shock is highly complex, and certain characteristics of this pathogenesis have led to considerable controversy and confusion regarding the true mechanisms of the septic shock syndrome.
Approximately 30 years ago, early studies of septic shock emphasized two distinct clinical syndromes (3) . One type had a bounding pulse ascribed to a high cardiac output; a second syndrome was characterized by "cold, clammy" skin and a faint pulse and this syndrome was postulated to result from a low cardiac output. This low cardiac output was equated with inadequate heart function and was designated the heart failure or myocardial depression ofseptic shock (4) (5) (6) . Because canine endotoxin models produced a low cardiac output, this animal model was felt to be characteristic of the low output syndrome (4) . However, subsequent studies demonstrated unequivocally that most patients had a normal or high cardiac output in the initial phases ofseptic shock (7) (8) (9) (10) (11) (12) (13) (14) (15) . Thus, ifmyocardial depression was indeed a part of septic shock in humans, a low cardiac output was not a sensitive reflection of cardiac dysfunction.
Recently, noting that the ejection fraction (EF),1 but not cardiac output, was an excellent predictor of ultimate prognosis in patients with chronic coronary disease (16), we employed both the thermodilution cardiac output and the radionuclidegated blood pool scan-determined EF in the intensive care environment, and showed that a significant subpopulation of patients with moderate-to-severe septic shock demonstrated profound reductions in left ventricular EF and concomitant dilatation ofthe ventricle; in patients who survived, this ventricular dysfunction was found to be reversible during a 7-10-day followup period (17) . The cardiac index in these same patients was either normal (2.5-3.5 liters/min. iM2) or elevated (>3.5 liters/ min* nm2). A previous study had demonstrated that 5 of 20 patients with sepsis without shock also demonstrated an initial reduction in left ventricular EF (18) . Thus, by employing radionuclide studies along with thermodilution cardiac outputs, evidence of early transient myocardial depression was clearly demonstrated in humans with septic shock.
The cause of this depressed myocardial performance was not known. In animal models of hemorrhagic and endotoxic shock, two suggested mechanisms were a depressed coronary blood flow or the presence ofa circulating myocardial depressant factor. Employing a thermodilution coronary sinus catheter, we found no evidence for a decrease in coronary blood flow during human septic shock (19) . Thus, we devised an in vitro model of myocardial cell performance to evaluate the presence of a circulating myocardial depressant substance and attempted to correlate the presence of this in vitro substance with the radionuclide-determined EF, a measure of in vivo myocardial performance. This paper details the results of that study. < 500 cells/mm3), and a localized site of culture positive infection, but negative blood cultures that were ascribed to concomitant treatment with broad-spectrum antibiotics (three patients). The clinical characteristics of these 20 patients are shown in Table I . Of the 20 patients with septic shock, 11 patients had serial hemodynamics, serial radionuclide scans, and serial blood drawing to allow comparison of the acute and recovery (n = 9) or the acute and presepsis (n = 2) measures of cardiovascular function; these serial tests also allowed comparison ofin vivo cardiovascular function with a measure ofin vitro myocardial cell performance (see below). In 9 of the 20 septic shock patients, initial hemodynamics and initial blood samples were obtained; however, serial blood samples were not obtained (due to early death or due to unavailability of personnel) and the initial values only were analyzed. These nine patients demonstrated similar serial cardiovascular parameters (i.e., a return to normal EF in survivors) as the 11 patients (Pl-PI 1) cited above.
Control populations. Three separate control populations (Table II) Hemodynamic evaluations. In the patients and the critically ill controls, arterial pressure was monitored by an indwelling arterial catheter in the radial or femoral artery. A pulmonary artery balloon flotation catheter was positioned with fluoroscopic guidance in the pulmonary artery of each patient. Serial measurements (every 6-12 h) of central venous pressure, pulmonary capillary wedge pressure, and cardiac output by thermodilution technique were obtained. Cardiac index was the cardiac output divided by a patient's body surface area. Measurements of pulmonary capillary wedge pressure were made from tracings on graph paper at end expiration. In patients on positive end expiratory pressure (see below), measurements of pulmonary capillary wedge pressure were made at end expiration both on and after 10 s off positive and expiratory pressure. In the patients in this study, the mean pulmonary capillary wedge pressure on and offpositive end expiratory pressure never differed by >2 mmHg.
Systemic vascular resistance index (SVRI) and stroke volume index (SVI) were calculated according to standard formulas: SVRI (dynes * s/ cm-5/m2) = (MAP -CVP) + (CI) X 80, and SVI (ml/beat iM2) = Cl
. HR, where MAP = mean arterial pressure, CVP = central venous pressure, CI = cardiac index, and HR = heart rate. Therapeutic protocol. All the patients and any hypotensive critically ill control patient were treated by the same group ofcritical care physicians employing the following sequential treatment protocol: the goal was to maintain a mean arterial pressure >60 mmHg. Initially, all patients received intravenous fluids to maintain a pulmonary capillary wedge pressure of 15 mmHg. Dopamine was then added if the patient remained hypotensive. If the patient required >20 /Ag/kg. min of dopamine, levarterenol was added, and the dopamine was tapered to 2-3 'Rg/kg. min in an attempt to preserve renal perfusion. All patients received broadspectrum antibiotic coverage, usually including an aminoglycoside, a cephalosporin, and a semisynthetic penicillin active against Pseudomonas aeruginosa. When blood culture results were obtained, the antibiotic agents were adjusted appropriately. Each patient in shock was given two doses of methylprednisolone, 30 mg/kg of body weight, one at the onset of shock, and the second 4-8 h later. All In vitro myocardial cellperformance assay. We devised a modification of previously described in vitro heart cell contractility system (21) (22) (23) (24) (25) (26) . These systems had been shown to be affected by addition of calcium or inotropic agents and were thus felt to reflect in vivo physiology.
Spontaneously beating newborn rat heart cell cultures were established employing a modification of the technique described by Harary and Farley (21) . Using sterile techniques, the ventricular muscle was dissected away from the atria and great vessels, cut into small 1-mm3 blocks of tissue, and exposed to trypsinization ( The extent and velocity of myocardial cell shortening during contraction was assayed by a modification of previously described techniques (27) . Fig. 1 Fig. 2 demonstrates the method employed to evaluate cell motion electronically. The edge of a contracting myocardial cell (at the end of contraction) was placed at the border of a video field. The density of the cell was greater than a specific density threshold that could be measured by the electronic circuit within the video field. The density threshold is adjustable and could be regulated to an appropriate level. Within the video field, the specific density was below that which the electronic circuit could measure. During myocardial cell relaxation, the cell (with its specific density above the measurable threshold) would occupy a significant amount of area within the video field. During contraction, the edge of the cells would move to the edge of the video field and occupy little or none of the area of the video field. The video field electronics had the ability to measure instantaneously the area within the video field above a specific density threshold. Thus, by plotting time versus the percentage of the video field area above a specific density threshold, an accurate representation of the extent of myocardial cell shortening (versus time) could be plotted. An electronic derivative of this extent of shortening would provide the velocity of myocardial cell contraction. The extent and velocity of cell shortening during contraction were recorded on a dual channel strip chart recorder. The electronic circuitry of this system has been explained in more detail in previous publications (27) . Serum was obtained from patients or controls by drawing blood into sterile glass test tubes, the blood was allowed to sit at room temperature (20'C) for 30 min and then spun at 1,000 g for 15 min, and then serum was pipetted in 0.5-ml aliquots into plastic tubes which were frozen at -70'C until assayed. Serum was obtained within 0.5 h of the cardiovascular evaluation to which it was compared. Initially, assays of myocardial cell extent and velocity ofshortening were performed immediately; however, it was found that there was no change in results when comparing assays performed on the same serum samples ifthe assay was performed within 6 mo of one another (see Table III ). Thus the depressant substance appeared to be stable at -70'C for at least 6 mo.
To evaluate the effects ofa specific serum sample, the test serum was diluted (10% serum) in a physiologic media consisting of 65% Dulbecco's BSS-K, and 25% Medium 199 (28 To determine the extent or velocity ofshortening for a test or control sera, 10 beats ofa myocardial cell extent and velocity ofshortening were measured and averaged. Test serum was initially run in duplicate samples until the reproducibility of samples was always <10%; then a single determination for each sample was performed. With 10 patients, test serums were repeated on a different day with a different group of heart cells in culture, and the reproducibility of any depression or enhancement was found to be <10% (usually <5%) for all these determinations. Thus, the assay demonstrated excellent reproducibility.
Preliminary experiments were performed to determine whether this in vitro assay was responsive to pharmacologic agents that were known to enhance or depress myocardial cell contractility. Table III ). Calcium concentrations (Table III) in increasing amounts induced an increase in extent (and to a lesser degree in velocity) ofshortening of myocardial cells during contraction. It should be noted that multiple samples of patient sera (10%) mixed with physiologic media were tested in this study and all test mixtures had a calcium level of 1.8 mm/ml because the 10% test sera were all diluted by a 90% media containing 1.8 mm/ml of calcium (see below for further explanation).
Effects of rate on myocardial performance in vitro. For several experiments, the beating rate of myocardial cells in vitro was increased by pacing the spontaneously beating cells at a faster than spontaneous rate.
A Medtronic 5375 demand pulse generator (Medtronic Inc., Minneapolis, MN) was attached to a 4 French USCI bipolar pacemaker electrode.
The electrode was passed through a hole in the petri dish and put on top of the beating myocardial cell monolayer. Employing a 20-mA output, the cells could be paced at rates up to 120 beats/min. Statistical evaluation. Comparisons between control and patient groups were performed using the paired or unpaired Student's t test. Spearman coefficients of rank correlation were calculated to evaluate the relationships between the in vitro myocardial cell performance and the in vivo radionuclide-determined EF. A P value of <0.05 was considered statistically significant.
Results
Examples ofserum-induced decreases in in vitro myocardial cell performance. Fig. 3 demonstrates several representative examples of the effect of serum from patients during the acute phase of septic shock on the in vitro performance of myocardial cell contraction. Acute-phase shock serum produced substantial decreases in both extent and velocity of shortening during contraction. After the test serum was removed from the cells, the base-line extent and velocity of shortening return.
No test serum reported in this study induced a change of >30 beats/min (only two patients changed their rate >20 beats/ min) in the rate of myocardial cell contraction. There was no consistent pattern of change between the change in rate and the change in performance, i.e., an increase or decrease in rate did not predict a similar change in extent or velocity of shortening.
Comparison ofpatient and control groups. Fig. 4 illustrates the percent change in extent of myocardial cell shortening induced by 10% serum obtained from control groups (normal laboratory personnel, patients with a decreased EF secondary to structural heart disease, and critically ill nonseptic controls) and from patients during the acute phase and during the recovery phase or the presepsis phase oftheir illness. Statistical comparison of the five groups reveals that the septic shock patients during the acute phase had a statistically significantly lower mean±standard error ofthe mean (SEM) percent change in amplitude (-33.0±4.0%, P < 0.001) when compared to any ofthe three control groups (-1.7±2.9% for laboratory personnel, -1.2±2.9% for structural heart disease, and -0.6±3.3% for critically ill nonseptic controls) or when compared to the recovery or presepsis patients (+ 1 1.9 + 5.0%). None of the three control groups demonstrated significant differences in extent of shortening. The recovery or presepsis patients had a statistically higher (+ 1 1.9 + 5.0%) mean extent of shortening when compared to any of the three control groups (P < 0.05).
The mean EF of the structural heart disease patients (0.288±0.023) and the acute-phase septic shock patients (0.329±0.029) were both significantly lower (P < 0.001) than the critically ill nonseptic controls (0.564±0.025) and the recovery or presepsis septic shock patients (0.503±0.047). The mean EF of the structural heart disease controls was similar to the mean EF of the acute-phase septic shock patients (P = NS). The mean EF ofthe critically ill septic shock controls was similar to the mean EF of the recovery or presepsis septic shock patients (P = NS). Fig. 5 illustrates that similar results were seen when analyzing the control and patient groups regarding the effect of serum on the velocity of myocardial cell shortening in vitro. The mean percent decrease (-24.6±3.9%) in myocardial cell velocity of shortening induced by 10% serum from patients during the acute phase of septic shock was significantly lower (P < 0.001) than that induced by laboratory personnel (+ 1.9±3.4%), controls with statistically significant (P < 0.001 comparing acute to recovery or presepsis phases of EF, amplitude, or velocity). All 11 patients demonstrated simultaneous increases in EFs, extent of myocardial cell shortening, and velocity of myocardial cell shortening while going from the acute to the recovery or presepsis phase of septic shock. If only nine patients (excluding the two patients who were nonsurvivors and had presepsis rather than recovery data) were used in the acute-and recovery-phase analysis, all of the statistical analyses remain highly statistically significantly different and were identical to those comparisons with 11 patients.
Comparison ofacute-and recovery-phase cardiovascular parameters other than EF. In addition to EFs, other cardiovascular parameters that could be determined from thermodilution cardiac indices, e.g., SVI, or calculated from radionuclide EF and thermodilution cardiac index, e.g., end diastolic volume index, were analyzed. These cardiovascular functional parameters were compared during the acute and recovery phases, and also compared to the in vitro amplitude and velocity of myocardial cell contraction.
In the 11 septic shock patients with acute and recovery (n = 9) or presepsis (n = 2) cardiovascular evaluations, in contrast to the EF which increased toward normal in every patient (see Fig. 6 ), the cardiac index changes were variable: five patients increased, five patients decreased, and one patient was unchanged. Similar variable changes were evident in stroke volume index. In these same I1 patients, the end diastolic volume index decreased toward normal in 10 patients, the only exception was in a nonsurvivor (patient P11 in Table I ). It should be noted that of the 20 septic shock patients (Table  I) , 17 patients are identical with those reported in a previous study (1 7) . For an analysis of the transient reversible changes in EF, cardiac index, stroke volume index, systemic vascular resistance index, and end diastolic volume index, evident in septic shock patients, the reader is referred to this previous study.
Correlation of EF with the extent of myocardial cell shortening. Fig. 7 illustrates the relationship between the radionuclidedetermined in vivo left ventricular EF and the in vitro percent change in extent of myocardial cell shortening in the 20 septic shock patients during the acute phase. Using the Spearman rank method, there was a statistically significant positive correlation between these two variables with an r value of +0.52 and a P < 0.01. Although a positive correlation was noted (r = +0. 19) between EF and myocardial cell velocity of shortening (no illustration), this relationship lacked statistical significance (P = NS).
As with EFs, Spearman rank correlations were performed between cardiac index, stroke volume index, and end diastolic volume index versus in vitro myocardial cell amplitude and velocity. No significant correlations were found between cardiac index or stroke volume index and any in vitro parameter. However, in the 20 acute-phase septic shock patients, the end diastolic volume index demonstrated a significant negative correlation (r = -0.41, P < 0.05) with the extent of myocardial cell shortening; no significant correlation was seen with velocity.
Evaluation ofother parameters that could potentially affect myocardial cell performance. As mentioned in Methods, all of the patients and controls in this study had frequent (every 4-6 h) measures of blood pH, Pco2, sodium, potassium, carbon dioxide, chloride, calcium, phosphate, magnesium, and glucose. All these electrolytes and metabolites were kept in the normal range. Because the myocardial contractility assay was performed on 10% test serum plus 90% physiologic media, the latter would tend to correct any abnormality due to electrolyte differences. We measured the 10% serum and media mixture for concentrations of Na, K, Ca, P04, Mg, and serum pH on 10 septic shock sera that produced depressions in myocardial extent of shortening and compared them to 10 sera and media mixture from 10 critically ill nonseptic patients. The electrolyte concentrations were essentially identical in these two groups. We concluded that electrolyte differences could not account for the differences in myocardial performance in vitro.
We analyzed the pharmacologic therapy of the patients and controls. Particular attention was paid to any pharmacologic agent that was felt to potentially affect cardiac function. No patient in this study was receiving digitalis, beta-blocking agents, or calcium channel-blocking agents. No serum was obtained within 3 h of a large dose of corticosteroids.
As mentioned in Methods, all these patients were treated by one group of critical care physicians according to a sequential protocol that began with fluid administration to increase the pulmonary capillary wedge pressure to 15 mmHg. The pulmonary capillary wedge pressure was very similar in the 20 acutephase septic shock patients (mean = 12.5 mmHg) and the 17 critically ill nonseptic control patients (mean = 13.2 mmHg, P = NS). If one employed the end diastolic volume index as a measure of preload (some authors would argue that end diastolic volume is a better measure of preload than pulmonary capillary wedge pressure [ 18] ), the acute-phase septic shock patients have a higher end diastolic volume than the critically ill nonseptic controls but they have a decreased ventricular performance despite a higher preload. We concluded that differences in preload cannot account for the differences between patients and controls.
Some patients were receiving the vasopressor agents dopamine and/or levarterenol. However, the septic shock patients The relationship between mechanical ventilation or the amount of positive end expiratory pressure versus the EF and the in vitro myocardial cell performance was investigated. In the 20 acute-phase septic shock patients, the 12 patients on mechanical ventilation had similar EFs and myocardial cell performance in vitro when compared to nonmechanically ventilated patients. In this group, patients on significant levels of positive end expiratory pressure (>5 cmH2O) also had similar EFs and myocardial cell performance in vitro when compared to patients on <5 cm or no positive end expiratory pressure. Several critically ill nonseptic patients were on mechanical ventilation and/or on positive end expiratory pressure and none demonstrated a decreased EF or a depressed in vitro myocardial cell performance. Thus, mechanical ventilation or positive end expiratory pressure could not account for the findings reported in this study.
Analysis of serial cardiovascular studies and serial in vitro myocardial cellperformance studies in nonsurviving patients. As shown in Fig. 6 , septic shock patients who survived would increase their EF toward normal, and the extent and velocity of in vitro myocardial cell performance increased toward control levels. One theory of myocardial dysfunction in septic shock (12) (13) (14) argued that nonsurvivors ofseptic shock would develop a myocardial depressant factor-induced progressive decrease in cardiac index during the late stage of the disease ultimately culminating in a low cardiac index-induced death. Ofthe 20 septic shock patients reported in this study (Table I) , six were nonsurvivors. One of these six, Pl0 (see Table I ), demonstrated a progressive decrease in both EF and cardiac index over an 1 l-d illness with a concomitant decrease in serum-induced depression of myocardial cell amplitude (from + 17% to -4 1%) and velocity. However, five ofthe six nonsurviving patients demonstrated no significant changes in cardiac index or EF over a 2-10.d (mean = 5 d) illness, and serum-induced depression of myocardial cell extent of shortening (from -17% to -17%) and velocity of shortening did not change as the patients approached their demise. Dose response ofdepressant serum. Fig. 8 demonstrates the dose-response characteristics ofserum from a representative patient (P4) during the acute phase of septic shock. Increasing the amount ofdepressant serum in the media applied to the beating myocardial cells resulted in a stepwise decrease in both the extent and velocity of shortening during myocardial cell contraction. This dose-response capability was demonstrable with any serum containing depressant activity.
Analysis ofthe effect ofmyocardial cell beating rate on extent and velocity ofmyocardial cell shortening. Table IV summarizes an experiment to evaluate the effect of myocardial cell rate on myocardial cell performance. Employing an exogenous pacemaker, the myocardial cell monolayer beating rate was increased from 30 to as high as 72 beats/min without any increase or decrease in extent or velocity of myocardial cell shortening.
Shock sera (10%) induced a decrease in extent (-36%) and velocity (-15%) of myocardial cell shortening at a spontaneous beating rate of 30/min. When the beating rate was increased to 48/min by the pacemaker, no significant change in extent or velocity of myocardial cell shortening was produced. Thus, changes in beating rate did not affect myocardial performance in vitro.
Experiments performed to characterize the molecular size and solubility characteristics ofmyocardial depressant substance. Tables V and VI summarize a series of experiments performed to characterize the size and solubility characteristics of the circulating depressant substance. Patient serum obtained during the acute phase ofseptic shock and containing depressant activity was placed in cellophane dialysis bags and dialyzed against a 1,000-mIl bath of 20 mm ofphosphate-buffered saline (PBS) with pH of 7.40 at 40C. The bath was replaced with fresh PBS every 12 h for a 48-h period. As controls, patient shock serum was kept in the same 40C cold room for 48 h. Dialyzed serum lost its depressant activity, whereas control nondialyzed serum retained the ability to depress extent and velocity of heart cell shortening. Thus, myocardial depressant substance can diffuse through a dialysis membrane. In general, molecules with a mol wt 10,000 or less can pass through this type of membrane. Thus, myocardial depressant substance probably has a mol wt <10,000. Although Table V contains data from two patients, this dialysis equipment has been performed on four shock patients with similar results to those shown. passage of only small molecules (<500 mol wt), the activity is retained in the residual (>500 mol wt) fraction (Table V B3 ).
Because salt, catecholamines, and most pharmacologic agents are found in the fraction with a mol wt <500, this experiment provides strong data against these substances accounting for de- * This experiment is a base-line study i.e., a different myocardial cell is being used and subsequent experiments will be compared to this base line. cardial cell contraction in an in vitro model of myocardial cell performance. Importantly, this depressant activity has been shown to be absent from serum obtained from normal laboratory personnel, from patients with reduced EFs due to structural heart disease, and from critically ill but nonseptic patients. Employing serial blood sampling and serial measures of cardiovascular function, this depressant activity has been shown to be present during the acute phase of septic shock but to be absent from recovery serum or from presepsis serum. During the acute phase of septic shock, the decreased EF and the increased end diastolic volume index (but not cardiac index or stroke volume index) significantly correlated with the depression in the extent of myocardial cell shortening in vitro. This correlation suggested that the amount of decrease in the extent of myocardial cell shortening in vitro was reflecting the pathophysiologic events responsible for myocardial depression during the acute phase of septic shock in vivo.
Previous studies have described a myocardial depressant factor in various forms ofshock (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) . However, these studies have been significantly flawed due to a variety of reasons, and a chapter reviewing our current understanding of shock in a recent major textbook of medicine (39) termed the presence and role of myocardial depressant factors as "controversial." Many of the previous studies did not include appropriate control groups, i.e., the studies did not demonstrate that depressant activity was absent from normals and absent from other critically ill patients who were not in shock. Other studies did not clearly demonstrate that exogenous medication or electrolyte abnormalities were not responsible for the myocardial depression. Critical investigators have noted that a high salt concentration probably accounted for cardiac depressant activity in a number of experimental systems (40) . Most of these previous studies have employed the canine hemorrhagic shock model, a model that is not clearly analogous to any form of human shock.
In addition, none of these studies have clearly related the presence of in vitro myocardial depression (usually employing a papillary muscle or Langendorf isolated heart preparation) to clear-cut cardiac depression in vivo. This relationship is very important and must be proven to exist in order to relate an in vitro phenomenon to the pathophysiologic mechanisms responsible for myocardial depression during shock in patients. Thus, in the present study, we have demonstrated the existence of a myocardial depressant substance in the blood of human septic shock patients early in their course, and quantitatively and temporally related the presense of this depressant activity to concomitant evidence of myocardial dysfunction as demonstrated by a decreased EF and left ventricular dilatation.
The relationship of this circulating myocardial depressant substance to the complex pathogenesis ofthe human septic shock syndrome is an important but only partially understood phenomena. The cardiovascular abnormalities characteristic of the human septic shock include both cardiac dysfunction and a peripheral vascular abnormality (41) . There is also evidence that the initial or early cardiovascular hemodynamic pattern may differ substantially from the hemodynamic abnormalities characteristic of the late phase of septic shock, especially the late phase in nonsurvivors (42) . Most of the data reported in this study reflects the early stages of the septic shock syndrome, a time characterized by a high or normal cardiac index, a decreased peripheral systemic vascular resistance, and, as recently demonstrated (17) , a decreased EF. Employing volume infusions in septic shock patients, two recent studies (43, 44) confirmed the presence of severe reversible myocardial dysfunction in the early phase of human septic shock. Thus, three studies have demonstrated evidence of in vivo myocardial dysfunction early in human septic shock, and the present study has provided evidence that in vitro myocardial depressant activity was clearly present during these initial few days in a large subpopulation of patients with septic shock.
Because patients during the early stages of septic shock have evidence of tissue ischemia with elevation of circulating lactic acid, one possible role of myocardial depressant substance would be to reduce cardiac output resulting in a less than maximal output for any particular patient. This could well contribute to peripheral tissue ischemia. This effect is probably not the major mechanism of tissue ischemia in that the cardiac index and stroke volume are normal or elevated in early septic shock; however, it may be a contributing factor. Maldistribution of peripheral blood flow probably accounts for most of the tissue ischemia (10) (11) (12) (13) (14) . In one nonsurviving patient in this study (patient PlO in Table I ), there were multiple serial measures of both cardiovascular function and myocardial depressant activity until the day of death. In this patient, myocardial depressant activity persisted in the serum until death, and the patient demonstrated serial decreases in cardiac indices and EFs that resulted in a low output syndrome and patient demise. The pattern in this one nonsurvivor suggested that myocardial depressant substance may occasionally cause severe myocardial dysfunction that becomes incompatible with life. However, this pattern is probably not common-most nonsurvivors (or survivors) do not develop a late decrease in either EF or cardiac index. Myocardial depressant activity has not been measured in enough patients to warrant generalizations regarding characteristic serial patterns.
The in vitro myocardial cell contractility assay employed in this study represented a modification of previously described cell culture methods (21) (22) (23) (24) (25) (26) (27) (28) ). These models have been shown to develop spontaneous beating rates and the cells respond to pharmacologic and physiologic agents with appropriate changes e.g., increases or decreases in beating rate or cell inotropy. The latter is usually measured as an increase or decrease in the extent and/or velocity of shortening ofa cultured heart cell. Electrolytes, catecholamines, thyroid hormones, and pharmacologic agents have produced appropriate changes in heart cell performance in vitro. As documented in Table III , the myocardial contractility model employed in the present studies responded appropriately to a wide variety of electrolytes and pharmacologic agents. Serum from control or septic patients produced little or only modest changes in beating rate, and the changes in rate were not correlated with changes in cell performance, i.e., extent or velocity of myocardial cell shortening.
Several methods were employed to exclude the possibility that the myocardial depression resulted from salt, electrolytes, pharmacologic agents, or other unsuspected substance. Several control groups were employed. The control group with structural heart disease excluded the possibility that all patients with decreased EFs produced a substance that decreased myocardial cell performance. The control group of critically ill nonseptic patients was included to exclude the possibility that all critically ill patients produce a "toxic" substance that could depress myocardial cell performance. This latter control group included several patients with hypovolemic shock (n = 3), cardiogenic shock (n = 1), and severe pericardial tamponade (n = 1). None ofthese nonseptic causes of shock were associated with a circulating myocardial depressant substance. Thus, unlike some canine models ofhypovolemic (hemorrhagic) or cardiogenic shock, humans with these nonseptic causes ofshock did not show evidence of a circulating myocardial cell depressant substance.
Another group of patients that provided a superb control comparison was the patients who recovered (n = 9) or had a presepsis (n = 2) blood sampling and ventricular performance studies. Serum obtained from these 11 patients during the acute phase of septic shock had clear evidence ofdepressed EF in vivo and a decreased myocardial cell performance in vitro; however, during the recovery phase ofpresepsis phase, these same patients had returned to normal or mildly enhanced in vitro myocardial cell performance. Thus, the myocardial depressant substance could be produced by a septic shock patient within a few hours (the earliest evidence of in vitro depression was obtained 2 h after the onset ofseptic shock), and the substance could be cleared from the serum within 2-3 d.
In addition to using several control groups, we have directly assayed the electrolyte concentrations in the serum/media mixture bathing the myocardial cells and found no differences in electrolyte concentrations between depressant and nondepressant serum/media mixtures. As judged by dialysis, Amicon filtration, and G-25 gel filtration, the molecular weight of the depressant substance (-2,000) was in a range inconsistent with any electrolyte, catecholamine, or other exogenous pharmacologic agent.
In recent years, a number ofserum substances with potential physiologic capabilities have been described. A recent study (45) characterized a serum factor that was capable of causing increased release of amino acids from skeletal muscle cells grown in vitro. Serum from patients with sepsis or trauma (clinical syndromes known to be associated with severe proteolysis and catabolism) demonstrated the most potent capability to induce release of amino acids. Previous studies (35, 36) of cultured rat myocardial cells have shown that sera from patients with sepsis could inhibit isoproterenol-induced increases in beating rate. The relationship of the depressant substance described in this study to those cited above will require further study.
The relationship of this myocardial depressant substance to survival of the patient deserves specific consideration. In a previous publication (17), we noted the somewhat paradoxical finding that septic shock patients with an initially depressed EF had a higher survival than patients with an initially normal or elevated EF. As can be seen in Figs. 4, 5, and 7, a normal or high EF was seen in many ofthe nonsurvivors. However, when we specifically analyzed the quantity of myocardial depression (extent and velocity of shortening) in vitro during the acute phase of septic shock, there were no significant differences between the survivors and nonsurvivors. Thus, although the amount of myocardial depressant substance positively correlated with the profound effect on ventricular function, the circulating depressant did not show a significant correlation with the survival in these patients. The relationship between myocardial depressant substance and prognosis will require further study and a better understanding of both the structure and function of this circulating depressant substance.
